The value of MEIS1 gene methylation assay in the noninvasive diagnosis of bladder cancer in urine

• Published in: Yixue xinzhi zazhi Vol. 35; no. 5; pp. 520 - 526
• Main Authors: ZHANG Zhenwei, TONG Zhichao, WANG Jianwei, LI Haonan, HU Sheng, WANG Ziqi
• Format: Journal Article
• Language: Chinese
• Published: Editorial Office of New Medicine 01.05.2025
• Subjects: bladder cancer; liquid biopsy; meis1 gene; methylation; noninvasive diagnosis
• ISSN: 1004-5511
• DOI: 10.12173/j.issn.1004-5511.202411183

Objective To analyze the value of MEIS1 gene methylation in the early diagnosis of bladder cancer (BCa).Methods From August 2023 to May 2024, BCa patients and non-tumor patients in the Harbin Medical University Cancer Hospital were selected as the modeling cohort. Urine and tissue samples were used to analyze the difference of methylation genes in combination with the data in the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to determine the specific methylation markers of BCa. BCa patients and non-tumor patients from June 2024 to October 2024 were selected as the validation cohort, and the diagnostic value of MEIS1 was analyzed by comparing with the pathological gold standard.Results A total of 297 subjects were included, including 94 BCa patients and 83 non- tumor patients in the modeling cohort, 90 BCa patients and 30 non-tumor patients in the validation cohort. Analysis of the modeling cohort, TCGA, and GEO data screened out 5 methylation sites, including HOXA9, CRTR, TWIST1, MEIS1, and